A Phase 4 Open-label, Randomized, Single Oral Dose, Two-way Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of Mirabegron in Healthy Chinese Subjects
Latest Information Update: 01 Nov 2021
At a glance
- Drugs Mirabegron (Primary)
- Indications Erectile dysfunction; Interstitial cystitis; Overactive bladder
- Focus Pharmacokinetics
- Sponsors Astellas Pharma China
- 30 Oct 2020 Status changed from recruiting to completed.
- 08 Oct 2020 Planned End Date changed from 1 Nov 2020 to 1 Oct 2020.
- 08 Oct 2020 Planned primary completion date changed from 1 Nov 2020 to 1 Oct 2020.